Currently out of the existing stock ratings of Andrew Peters, 31 are a BUY (96.88%), 1 are a HOLD (3.13%).

Andrew Peters

Work Performance Price Targets & Ratings Chart

Analyst Andrew Peters, carries an average stock price target met ratio of 86.75% that have a potential upside of 39.29% achieved within 660 days. Previously, Andrew Peters worked at DEUTSCHE BANK, UBS.

Andrew Peters’s has documented 77 price targets and ratings displayed on 9 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ESPR, Esperion Therapeutics at 03-May-2018.

Wall Street Analyst Andrew Peters

Analyst best performing recommendations are on EXEL (EXELIXIS).
The best stock recommendation documented was for HALO (HALOZYME THERAPEUTICS) at 11/3/2016. The price target of $12 was fulfilled within 7 days with a profit of $3.54 (41.84%) receiving and performance score of 59.78.

Average potential price target upside

of $32.26 (25.94%) on ALXN (ALEXION PHARMACEUTICALS).
of $23.44 (26.51%) on BMRN (BIOMARIN PHARMACEUTICAL).
of $21.5 (36.82%) on GILD (GILEAD SCIENCES).

BMRN Biomarin Pharmaceutical GILD Gilead Sciences HALO Halozyme Therapeutics NBIX Neurocrine Biosciences ACHN Achillion Pharmaceuticals ALXN Alexion Pharmaceuticals ESPR Esperion Therapeutics PRTA Prothena plc EXEL Exelixis

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Andreas Argyrides (WEDBUSH)